Skip to content

Press Releases and Events

PRESS RELEASES AND EVENTS

Events

There are currently no events to display.

Archived Events

There are currently no events to display.

Press Releases

Date Title and Summary View
Toggle Summary Intra-Cellular Therapies to Host First Quarter 2016 Financial Results Conference Call and Webcast
NEW YORK, April 21, 2016 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced that it will host a conference call and live webcast discussion at 8:30 a.m.
View HTML
Toggle Summary Intra-Cellular Therapies Presents Additional ITI-007 Data at the 5th Biennial Schizophrenia International Research Society (SIRS) Conference
NEW YORK, April 06, 2016 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (NASDAQ:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced it delivered an oral presentation and presented several posters featuring
View HTML
Toggle Summary Intra-Cellular Therapies to Present at the 15th Annual Needham Healthcare Conference
NEW YORK, April 04, 2016 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system ("CNS") disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and Chairman, is
View HTML
Toggle Summary Intra-Cellular Therapies Announces Upcoming Presentations at the 5th Biennial Schizophrenia International Research Society Conference
NEW YORK, March 30, 2016 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (NASDAQ:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced that one oral presentation and three posters on ITI-007, the Company's lead
View HTML
Toggle Summary Intra-Cellular Therapies to Present at the Cowen and Company 36th Annual Health Care Conference
NEW YORK, Feb. 29, 2016 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system ("CNS") disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and Chairman, is scheduled
View HTML
Toggle Summary Intra-Cellular Therapies Reports Fourth Quarter and Full-Year 2015 Financial Results and Provides Corporate Update
NEW YORK, Feb. 25, 2016 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (NASDAQ:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced its financial results for the fourth quarter and year ended December 31, 2015,
View HTML
Toggle Summary Intra-Cellular Therapies to Host Fourth Quarter and Full-Year 2015 Financial Results Conference Call and Webcast
NEW YORK, Feb. 18, 2016 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced that it will host a conference call and live webcast discussion at 8:30 a.m.
View HTML
Toggle Summary Intra-Cellular Therapies to Present at the 2016 RBC Capital Markets' Healthcare Conference
NEW YORK, Feb. 16, 2016 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system ("CNS") disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and Chairman, is scheduled
View HTML
Toggle Summary Intra-Cellular Therapies to Present at the Leerink Partners' 5th Annual Global Healthcare Conference View HTML
Toggle Summary Intra-Cellular Therapies Reports Initiation of Patient Enrollment for ITI-007 Phase 3 Clinical Trials in Bipolar Depression
NEW YORK, Dec. 23, 2015 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced initiation of enrollment for the Phase 3 clinical trials in the Company's
View HTML
Toggle Summary Intra-Cellular Therapies to Present at the 34th Annual J.P. Morgan Healthcare Conference
NEW YORK, Dec. 21, 2015 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system ("CNS") disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and Chairman, is
View HTML
Toggle Summary Intra-Cellular Therapies Presents Additional Efficacy and Safety Data From the Positive Phase 3 Clinical Trial of ITI-007 for the Treatment of Schizophrenia and From the Positron Emission Tomography Study
Intra-Cellular Therapies to Host a Conference Call Thursday, December 10, 2015 at 8:30 am EST to Discuss the Data
View HTML
Toggle Summary Intra-Cellular Therapies to Present at the 54th Annual Meeting of the American College of Neuropsychopharmacology View HTML
Toggle Summary Intra-Cellular Therapies to Participate at Upcoming Investor Conferences View HTML
Toggle Summary Intra-Cellular Therapies to Present at Jefferies Autumn 2015 Global Healthcare Conference in London View HTML